Health
Human recombinant soluble ACE2 successfully used in a patient with severe COVID-19 – News-Medical.Net
A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.
A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.
A pandemic spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for almost one million deaths due to COVID-19. Therefore, important insights into the viral pathophysiology may facilitate the quest for an eff…
-
Business22 hours agoBroker names 2 small cap ASX shares to buy for big returns
-
Business21 hours agoThese top ASX 200 stocks could rise 25% to 60%
-
Noosa News23 hours agoTributes continue to flow | Noosa Today
-
Noosa News22 hours agoMin Woo Lee, Adam Scott and Cameron Smith in the mix after Australian PGA opening round in Brisbane